Every Form 4 that Enliven Therapeutics, Inc. (ELVN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELVN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELVN filings page.
Director J. Scott Garland exercised options covering 13,000 ELVN shares on October 1, 2026, at an exercise price of $15.47 per share, acquired 13,000 common shares, and sold 13,000 shares at a weighted average $46.6707 per share. The reported sale prices ranged from $46.62 to $46.87 per share. The reported option position was 46,372 shares following the exercise. No Rule 10b5-1 plan is reported.
Enliven Therapeutics, Inc. (ELVN) reported that its chief financial officer, Benjamin Hohl, exercised stock options for 3,982 shares of Common Stock at an exercise price of $14.85 per share on September 17, 2026. The same day, he sold a total of 6,018 shares of Common Stock in multiple trades at weighted-average prices between about $50.03 and $51.49. Following the option exercise, he held 181,018 stock options from the original grant, and certain equity holdings are in the form of restricted stock units. All reported trades were effected under a Rule 10b5-1 trading plan adopted on March 18, 2026.
Enliven Therapeutics, Inc. (ELVN) reported that Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares of Common Stock on September 17, 2026 at an exercise price of $2.48 per share and then sold 5,000 shares the same day in open-market transactions. The sales occurred in three tranches at weighted average prices of about $50.03, $50.71 and $51.48 per share, within ranges from $49.305 to $51.675, and were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025. After the option exercise, Collins held 106,268 options that are fully vested and exercisable.
Enliven Therapeutics, Inc. (ELVN) reported that its Chief Financial Officer, Benjamin Hohl, sold shares of the company’s Common Stock in two open-market transactions on August 17, 2026. He sold 4,630 shares at a weighted average price of $58.3517 per share and 1,388 shares at a weighted average price of $59.3536 per share, totaling 6,018 shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. A portion of the securities associated with his holdings are restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock, subject to vesting conditions.
Enliven Therapeutics, Inc. (ELVN) reported that Chief Medical Officer Helen Louise Collins exercised a stock option for 5,000 shares of common stock at an exercise price of $2.48 per share and on the same date sold 5,000 shares in two open-market transactions at weighted average prices of $58.3717 and $59.3465. Following the option exercise, she held 111,268 option shares directly. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Enliven Therapeutics, Inc. director Mika K. Derynck exercised stock options covering 158,795 shares of common stock on August 4, 2026 at exercise prices of $2.4800, $14.8500, $22.4700 and $25.2800 per share.
He then sold 158,795 shares at a weighted average price of $60.2134 per share, in multiple trades between $60.00 and $60.58, pursuant to a Rule 10b5-1 trading plan adopted on April 8, 2025. All options exercised were fully vested and exercisable.
Enliven Therapeutics CFO Benjamin Hohl reported an option exercise and related share sales on July 17, 2026. He exercised stock options covering 1,072 shares of common stock at an exercise price of $2.48 per share and sold 6,018 common shares in open-market transactions pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. Following the exercise, he held 84,966 stock options for Enliven common stock.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 5,000 shares of common stock at $2.48 per share on July 17, 2026, then sold 5,000 shares in multiple trades at weighted average prices between $49.72 and $53.93. After the exercise, she reported directly holding 116,268 stock options. All transactions were effected under a pre-established Rule 10b5-1 trading plan adopted on October 19, 2025.
Enliven Therapeutics, Inc. director Lori Anne Kunkel reported selling a total of 10,000 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices of $50.8442 and $49.9834 per share.
According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, indicating the sales were scheduled in advance rather than timed discretionarily.
Enliven Therapeutics, Inc. reported that investment entities affiliated with OrbiMed executed open-market sales of its Common Stock. On June 22, 2026, the entities sold a combined 860,123 shares of Enliven at prices around $45–$45.38 per share.
After these transactions, one OrbiMed-affiliated fund reported 6,601,878 shares of Enliven Common Stock indirectly owned, while another reported 6,555,102 shares. The OrbiMed reporting entities and their related general partners and adviser disclaim beneficial ownership of the securities beyond any pecuniary interest.
Enliven Therapeutics, Inc. chief financial officer Benjamin Hohl exercised stock options and sold shares of common stock in coordinated transactions. He exercised options for 6,018 shares at an exercise price of $2.48 per share and then sold 6,018 shares in several open-market trades on June 17, 2026 at weighted average prices between $42.79 and $44.75 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Hohl directly holds 51,000 shares of Enliven common stock, indicating he retains a meaningful equity stake in the company.
Enliven Therapeutics, Inc. chief medical officer Helen Louise Collins reported a mix of option exercise and share sales in the company’s stock. On June 17, 2026, she exercised options for 5,000 shares of common stock at a strike price of $2.48 per share, then sold a total of 5,000 shares in three open-market transactions at weighted average prices of $42.8270, $43.8701 and $44.7430 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025. Following the transactions, she holds 25,000 shares of common stock directly and 121,268 stock options.
Enliven Therapeutics, Inc. disclosed that investment entities affiliated with OrbiMed executed open-market sales of its Common Stock. OrbiMed-related holders sold 272,322 shares at $45.02 per share and an additional 9,086 shares at the same price. After these transactions, the reporting entities’ indirect holdings reported in this filing were 7,388,902 shares and 245,728 shares, respectively. Footnotes explain that OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP hold the shares of record, and OrbiMed-affiliated general partners and OrbiMed Advisors may be deemed to share voting and investment power while disclaiming beneficial ownership beyond any pecuniary interest.
Enliven Therapeutics director Lori Anne Kunkel reported open-market sales of 10,000 shares of Enliven Therapeutics, Inc. common stock on June 5, 2026, executed in multiple trades under a Rule 10b5-1 trading plan adopted on March 6, 2026.
The shares were sold in three transactions at weighted average prices of $34.2794, $35.3573, and $35.8187 per share. After these sales, she held 51,884 shares of common stock directly.
Enliven Therapeutics, Inc. Chief Medical Officer Helen Louise Collins reported both stock sales and an option exercise in the company’s shares. On May 18, 2026, she sold a total of 5,000 shares of Common Stock in open-market transactions at prices including $39.5340, $40.2473 and $41.2052 per share.
On the same date, she exercised a stock option to acquire 5,000 shares of Common Stock at an exercise price of $2.4800 per share. Following these transactions, she directly owned 25,000 shares of Common Stock and held 126,268 stock options exercisable at $2.4800 per share, expiring on June 17, 2031. The filing notes that the option exercise and related sales were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Enliven Therapeutics chief medical officer Helen Louise Collins exercised stock options and sold shares in a pre-planned set of trades. On April 17, 2026, she exercised options to acquire 5,000 shares of common stock at $2.48 per share, then sold 5,000 shares in open-market transactions at weighted average prices around $45.81–$48.06, all under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of Enliven common stock.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 40,000 shares of common stock at an exercise price of $2.48 per share and sold 40,000 shares at a weighted average price of $35.1006 per share. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating they were pre-scheduled. Following the transactions, Collins directly owns 25,000 shares of common stock and continues to hold 136,268 equity awards, including fully vested options and RSUs.
Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares of Common Stock at an exercise price of $2.4800 per share, then sold 5,000 shares at a weighted average price of $27.7600 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025. Following the sale, Collins directly holds 25,000 shares of Common Stock, and the filing shows no remaining derivative securities from this option after the exercise.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 40,000 shares of Common Stock at an exercise price of $2.48 per share, then sold 40,000 shares in open‑market trades at weighted average prices around $30.
The transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 19, 2025. After these trades, Collins holds 25,000 shares of Enliven Therapeutics Common Stock directly.
Enliven Therapeutics’ chief financial officer, Benjamin Hohl, sold 10,000 shares of common stock in an open-market transaction on March 6, 2026, at a weighted-average price of $29.5839 per share. After this sale, he directly owned 51,000 shares. The transaction was executed in multiple trades within a price range of $29.43 to $29.7867.
Enliven Therapeutics director Richard A. Heyman reported an open-market sale of 1,230 shares of common stock at a weighted average price of $26.1759 per share. The sale was made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024 for an associated trust account.
After this transaction, the filing shows 22,647 shares remaining in the indirectly held account that sold the shares, additional indirect holdings of 25,545 shares, and 123,673 shares held directly. Certain indirect holdings are through the Heyman Daigle Trust and RAHD Capital LLC, entities for which he serves as trustee or managing member.
Enliven Therapeutics, Inc.’s Chief Medical Officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 45,000 shares at $2.48 per share, converting them into 45,000 shares of common stock.
She then sold 45,000 common shares at a weighted average price of $26.1747, with trade prices ranging from $25.76 to $26.695, under a Rule 10b5-1 trading plan adopted on October 19, 2025. After these transactions, she directly held 25,000 shares of common stock and 221,268 option shares, all of which were fully vested and exercisable as of the transaction date.
Kunkel Lori Anne reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Lori Anne Kunkel received a new stock option grant covering 17,126 shares of the company’s stock. The option was awarded as a derivative security and is held directly. According to the terms, all shares vest in a single installment.
The option will fully vest on the earlier of the first anniversary of Enliven’s 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, provided Kunkel continues serving as a non-employee director through that vesting date.
Enliven Therapeutics director Richard A. Heyman received a grant of stock options for 19,234 shares of Enliven common stock. The options have an exercise price of $0.00 per share. They vest 100% on the earlier of the first anniversary of the 2026 annual stockholder meeting or the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director.
Gupta Rishi reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Rishi Gupta reported stock option grants. He was awarded options covering 33,989 shares and 1,580 shares. For the larger grant, 1/36 of the shares vest monthly starting on February 2, 2026, while the smaller grant fully vests around the company’s 2027 annual stockholder meeting.
Garland J. Scott reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics director Garland J. Scott reported receiving a grant of stock options covering 1,427 shares of common stock. The award was made at a reported price of $0.00 per share.
All 1,427 options will vest in full on the earlier of the first anniversary of Enliven's 2026 annual stockholder meeting or the date of its 2027 annual meeting, as long as Scott continues serving as a non-employee director through that vesting date.
Enliven Therapeutics, Inc. reported that director Mika K. Derynck acquired a stock option covering 17,126 shares of common stock. This was a granted award, bringing the director’s directly held stock options to 17,126 shares following the transaction.
According to the terms, 100% of the shares subject to the option will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as the director continues serving as a non-employee director through the applicable vesting date.
Enliven Therapeutics director Jake Bauer reported a new equity award. He received a grant of stock options covering 17,126 shares at an exercise price of $0.00 per share. According to the terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as he continues serving as a non-employee director through that vesting date.
Ballal Rahul D. reported acquisition or exercise transactions in this Form 4 filing.
Enliven Therapeutics, Inc. reported that director Rahul D. Ballal received a grant of 17,126 stock options. The transaction is coded as a grant or award and recorded with a transaction price of $0.00 per option.
According to the vesting terms, 100% of these options will vest on the earlier of the first anniversary of the 2026 annual stockholder meeting or the date of the 2027 annual stockholder meeting, as long as Ballal continues serving as a non-employee director through that vesting date.
Enliven Therapeutics reported new equity awards for Chief Operating Officer Anish Patel. On February 12, 2026, he received a stock option covering 120,000 shares of common stock at an exercise price of $0.00 per share, vesting 25% on February 12, 2027 and the remainder in equal monthly installments thereafter. He also acquired 20,000 restricted stock units, each representing one share of common stock, with 25% vesting on March 1, 2027 and the balance vesting in equal installments each June 1, September 1, December 1, and March 1 thereafter, while he continues as a service provider. In addition, an indirect holding of 215,011 common shares is reported as held by The Patel / Dong Family Trust, for which he serves as trustee.
Enliven Therapeutics, Inc. reported an equity compensation award to its Chief Scientific Officer, Joseph P. Lyssikatos. On February 12, 2026, he was granted a stock option for 112,500 shares of common stock at an exercise price of $0.00 per share. According to the filing, one quarter of this option vests on February 12, 2027, with the remainder vesting in equal monthly installments over the following three years, so long as he continues as a service provider.
He also received 18,750 restricted stock units (RSUs), each representing one share of common stock. One quarter of these RSUs vest on March 1, 2027, with additional portions vesting on each June 1, September 1, December 1, and March 1 thereafter, subject to continued service. The filing also notes indirect ownership of 740,188 shares of common stock held through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
Enliven Therapeutics reported new equity awards for its Chief Financial Officer, Benjamin Hohl. He received stock options for 150,000 shares at an exercise price of $0.00 per share and 25,000 restricted stock units, each representing one share of common stock.
The option award vests over four years, with one-quarter vesting on February 12, 2027 and the remainder monthly thereafter, as long as he continues as a service provider. The RSUs vest on a similar multi-year schedule beginning March 1, 2027, with one-quarter vesting initially and the rest in equal quarterly installments.
Collins Helen Louise reported acquisition or exercise transactions in a Form 4 filing for ELVN. The filing lists transactions totaling 175,000 shares. Following the reported transactions, holdings were 150,000 shares.
Enliven Therapeutics’ chief scientific officer, Joseph P. Lyssikatos, reported an indirect sale of company stock through a family trust. On February 6, 2026, The Lyssikatos Revocable Trust sold 5,000 shares of Enliven common stock at a weighted average price of $29.0438 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024.
After this transaction, the trust, for which Lyssikatos serves as trustee, beneficially owned 740,188 shares of Enliven Therapeutics common stock, reported as indirectly owned.
The Lyssikatos Revocable Trust 12/15/2011, for which Enliven Therapeutics’ Chief Scientific Officer Joseph P. Lyssikatos serves as trustee, reported pre‑planned sales of company common stock. On January 20, 2026, the trust sold 5,491 shares at a weighted average price of $26.373 per share and a further 14,509 shares at a weighted average price of $26.8995 per share, each under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following these transactions, the trust held 745,188 shares of Enliven Therapeutics common stock indirectly attributable to the reporting person.
Enliven Therapeutics, Inc. director Richard A. Heyman reported planned sales of company common stock by related entities. On January 20, 2026, the Heyman Daigle Trust, for which he serves as trustee, sold 512 shares at $26.4592 and 718 shares at $26.956 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024. After these transactions, the trust held 23,877 shares beneficially for him. Heyman also reported 123,673 shares held directly and 25,545 shares held indirectly through RAHD Capital LLC, where he is a managing member.
Enliven Therapeutics, Inc. reported an insider transaction involving its Chief Operating Officer, Anish Patel, through an associated family trust. On January 9, 2026, The Patel / Dong Family Trust, for which Patel serves as trustee, sold 48,057 shares of Enliven common stock at a weighted average price of $27.9842, and an additional 243 shares at $28.50.
The filing states these sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024, which is a pre-arranged plan for trading the issuer’s equity securities. After these transactions, the trust held 215,011 shares of Enliven common stock, all reported as indirectly owned.
Enliven Therapeutics, Inc. insider activity shows that a trust associated with Chief Scientific Officer Joseph P. Lyssikatos sold a total of 132,500 shares of common stock in early January 2026. The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee, reported sales of 7,500 shares at a weighted average price of $20.1282 on 01/08/2026, followed by 33,802 shares at $24.9238 on the same date. On 01/09/2026, the trust sold 41,198 shares at a weighted average price of $24.9008 and 50,000 shares at $29.1343. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 15, 2024, and after the final sale, the trust beneficially owned 765,188 shares.
Enliven Therapeutics director Richard A. Heyman reported indirect sales of the company’s common stock through entities associated with him. On January 8, 2026, RAHD Capital LLC, for which he serves as a managing member, sold 1,620 shares at $25.00 per share under a Rule 10b5-1 trading plan adopted on November 15, 2024, and held 25,545 shares of Enliven common stock indirectly afterward.
Also on January 8, 2026, the Richard A. Heyman and Anne E. Daigle Trust sold 8,015 shares at a weighted average price of $25.035, and on January 9, 2026 sold a further 4,285 shares at $25.0001, both under a Rule 10b5-1 plan and held 29,392 shares indirectly afterward. In addition, Heyman is reported as directly beneficially owning 123,673 shares of Enliven common stock.
Enliven Therapeutics director Garland J. Scott reported a new stock option grant on a Form 4. On January 7, 2026, he was awarded a stock option to buy 59,372 shares of Enliven Therapeutics, Inc. common stock at an exercise price of $15.47 per share, expiring on January 7, 2036. The filing states that one‑thirty‑sixth of the shares subject to the option will vest on February 7, 2026 and then monthly thereafter, as long as he continues serving as an outside director on each vesting date. The option is reported as directly owned and was granted at a price of $0 for the derivative itself.
Enliven Therapeutics, Inc. (ELVN) disclosed that its Chief Scientific Officer filed a Form 4 reporting planned stock sales. On 11/19/2025, indirect holdings of common stock sold 12,008 shares at a weighted average price of $22.3013 and 492 shares at a weighted average price of $23.091, both coded as open market sales. These transactions were made under a Rule 10b5-1 trading plan adopted on November 15, 2024, which pre-schedules trades. After these sales, the reporting person’s trust beneficially owned 902,688 shares of Enliven common stock held through The Lyssikatos Revocable Trust 12/15/2011, where the officer serves as trustee.
Enliven Therapeutics, Inc. (ELVN) President, CEO and Director reported a sale of company stock in a Form 4 filing. On 11/17/2025, the reporting person sold 12,500 shares of common stock at a weighted average price of $21.8191, with individual trade prices ranging from $21.37 to $22.3537. The transaction is marked as a sale and was executed under a Rule 10b5-1 trading plan that was adopted on November 15, 2024, which is a pre-arranged plan designed to systematically sell shares over time. After this transaction, the reporting person indirectly beneficially owns 890,392 shares, held by The Kintz & Egan Trust Dated March 30, 2019, where the reporting person serves as trustee.
Enliven Therapeutics (ELVN) disclosed insider transactions by its Chief Operating Officer. On 11/07/2025, the reporting person executed sales of 6,054 shares at a weighted average price of $17.3503 and 613 shares at a weighted average price of $17.9371, effected under a Rule 10b5-1 trading plan adopted on September 30, 2024.
The trades were completed in multiple transactions within disclosed price ranges, and the shares are held indirectly by The Patel / Dong Family Trust, for which the reporting person serves as trustee. Following the reported sales, beneficial ownership stood at 269,974 shares held indirectly.
Enliven Therapeutics (ELVN) reported an insider transaction by its Chief Scientific Officer on Form 4. The filing shows a sale of 12,500 shares of common stock on October 20, 2025 at a weighted average price of $22.082, executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. Following the sale, the reporting person beneficially owned 915,188 shares, held indirectly through The Lyssikatos Revocable Trust dated 12/15/2011.
The transaction price ranged from $21.285 to $22.36, with full trade details available upon request.
Enliven Therapeutics (ELVN) reported an insider transaction: its President & CEO and Director sold 12,500 shares of Common Stock on 10/17/2025 at a $21.3323 weighted average price. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.
The transaction was executed in multiple trades within a price range of $21.1303 to $21.88. Following the sale, the reporting person beneficially owned 902,892 shares, held indirectly by The Kintz & Egan Trust Dated March 30, 2019.